Ginkgo Biloba Prevention Trial in Older Individuals
National Center for Complementary and Integrative Health (NCCIH)
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 3069
- sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- conditions
- Dementia; Alzheimer's Disease
- interventions
- DRUG: Ginkgo biloba; DRUG: Placebo
- start date
- 2000-10-01
- primary completion date
- 2008-04-01
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT00010803
- Published
- Feb 5, 2001
- Updated
- Mar 14, 2013
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT00010803
- Categories
- Dementia, Alzheimer's Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials